Talphera (NASDAQ:TLPH) vs. Lexaria Bioscience (NASDAQ:LEXX) Head-To-Head Comparison

Lexaria Bioscience (NASDAQ:LEXX) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Valuation and Earnings

This table compares Lexaria Bioscience and Talphera”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710,000.00	7.53	-$11.90 million	($5.10)	-0.64
Talphera	$30,000.00	2,007.19	-$14.29 million	($0.27)	-4.30

Lexaria Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Lexaria Bioscience has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Lexaria Bioscience and Talphera, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1	0	1	0	2.00
Talphera	1	1	2	0	2.25

Lexaria Bioscience currently has a consensus target price of $22.50, indicating a potential upside of 594.44%. Talphera has a consensus target price of $3.00, indicating a potential upside of 158.62%. Given Lexaria Bioscience’s higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Talphera.

Insider and Institutional Ownership

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Lexaria Bioscience and Talphera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Talphera	N/A	-87.28%	-51.36%

Summary

Talphera beats Lexaria Bioscience on 8 of the 13 factors compared between the two stocks.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.